Health Economics›Breast cancer›Metastatic disease, all lines of therapy

Metastatic disease, all lines of therapy

Breast cancer · 15 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

FiltersBiomarker

Y-axis

Cost vs Efficacy

No data points — cost or PFS missing for current selection.

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Medroxyprogesterone acetate monotherapy Variant #01	—	R 20 823	28d	—	~6.0 mo	~2	~R 41 646 PFS proxy · indirect	1
CAF and MPA Variant #01	—	R 12 933	28d	—	—	~3	~R 38 799 indirect	—
CTCb Variant #01 Partial	—	R 6 855	—	—	~24.0 mo	~1	~R 6 855 PFS proxy · indirect	1
Estradiol monotherapy Variant #01	—	R 2 346	28d	—	—	~2	~R 4 693 indirect	—
STAMP-I Variant #01 Partial	—	R 2 292	—	—	—	~1	~R 2 292 indirect	—
CAV Variant #06	—	R 865	21d	—	~7.6 mo	~6	~R 5 188 PFS proxy · indirect	1
VAP Variant #01	—	R 844	21d	—	—	~2	~R 1 688 indirect	—
TAD (Tamoxifen) Variant #01 Partial	—	R 487	28d	—	—	~2	~R 974 indirect	—
Fluoxymesterone and Tamoxifen Variant #01 Partial	—	R 137	28d	—	—	~2	~R 273 indirect	—
Aminoglutethimide monotherapy Variant #01 Partial	—	—	28d	—	—	~2	—	—
Megestrol monotherapy Variant #01 Partial	—	—	28d	—	—	~2	—	—
Formestane monotherapy Variant #01 Partial	—	—	14d	—	—	~2	—	—
Bilateral Oophorectomy Partial	ER	—	—	—	—	—	—	—
Fluoxymesterone monotherapy Variant #01 Partial	—	—	28d	—	—	~2	—	—
DES monotherapy Variant #01 Partial	—	—	28d	—	—	~2	—	—

15 of 15 regimens shown